drugset / Trial / NCT01111331

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

NCT01111331

Phase 1 Completed 18 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the current study is to investigate the bioavailability of BI 10773 and of warfarin after concomitant multiple oral administration of BI 10773 and a single oral dose of warfarin in comparison to BI 10773 and warfarin given alone, and to investigate the pharmacodynamics of a single oral dose of warfarin with and without concomitant multiple oral administration of BI 10773.

Timeline

Start
2010-05
Primary completion
2010-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg Oral
Subject Warfarin Small molecule 25 mg Oral

Indications

No indication recorded.